A phase 2 study of fruquintinib in combination with S-1 for second-line treatment of esophageal squamous cell carcinoma after first-line immunotherapy failure.

被引：0
|
作者：
Li, Ningning
Ge, Yuping
Wang, Xiang
Qiu, Wei
Zhang, Zhiyang
Zhou, Na
Zhao, Lin
机构：
[1] Peking Union Med Coll Hosp, Beijing, Peoples R China
[2] Peking Union Med Coll Hosp, Dept Med Oncol, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
261-374; 283-424-6846-271-2644; 298-145-222-7468; 261-566-148; 130-540-543-4790; 613-135-244-3829-325; 261-492-2769; 4; 3; 2; 2461; 6;
D O I：
10.1200/JCO.2024.42.3_suppl.323
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：323 / 323
页数：1
相关论文
共 50 条
  • [31] New First-Line Systemic Treatment Options for Metastatic Esophageal Squamous Cell Carcinoma
    Gibson, Michael K.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 (5.5): : 579 - 582
  • [32] Efficacy of S-1 plus nedaplatin compared to standard second-line chemotherapy in EGFR-negative lung adenocarcinoma after failure of first-line chemotherapy
    Tang, Yu
    Wang, Wei
    Teng, Xiu-Zhi
    Shi, Lin
    TUMOR BIOLOGY, 2014, 35 (09) : 8945 - 8951
  • [33] Docetaxel, cisplatin and S-1 as first and second-line regimen in patients with unresectable esophageal cancer
    Yoji, Nakamura
    Tadashi, Nishimaki
    Hideaki, Shimoji
    Hiroyuki, Karimata
    ANNALS OF ONCOLOGY, 2017, 28
  • [34] Apartinib in combination with S-1 for the second-line treatment of advanced pancreatic cancer (APC)
    Hang, Junjie
    Wu, Lixia
    Yin, Ruohan
    Liu, Muhan
    Xu, Kequn
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [35] Qualitative study of patients' decision-making when accepting second-line treatment after failure of first-line chemotherapy
    Pujol, Jean-Louis
    Roch, Benoit
    Roth, Caroline
    Merel, Jean-Pierre
    PLOS ONE, 2018, 13 (05):
  • [36] Compared Efficacy of Second-Line Treatments for Ulcerative Colitis After Failure of Vedolizumab in First-Line Treatment: A Retrospective Multicenter Study
    Calmejane, L.
    Reenaers, C.
    Amiot, A.
    Nuzzo, A.
    Vuitton, L.
    Altwegg, R.
    Guillo, L.
    Wils, P.
    Roblin, X.
    Le Cosquer, G.
    Simon, M.
    Benezech, A.
    Laharie, D.
    Fumery, M.
    Buisson, A.
    Charkaoui, M.
    Nancey, S.
    Sabra, G.
    Geyl, S.
    Coffin, B.
    Cavicchi, M.
    Le Berre, C.
    Goutorbe, F.
    Bouguen, G.
    Vidon, M.
    Christmann, P. Y.
    Kirchgesner, J.
    Uzzan, M.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I699 - I699
  • [37] A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma
    Wang, Hai-ying
    Yao, Zhi-hua
    Tang, Hong
    Zhao, Yan
    Jin, Shui-ling
    Zhou, Wen-ping
    Yao, Shu-na
    Yang, Shu-jun
    Liu, Yan-yan
    Luo, Su-xia
    ONCOTARGET, 2017, 8 (05) : 7540 - 7547
  • [38] Evaluation of Namibia's antiretroviral therapy guidelines' recommendations for switching from first-line to second-line, using predictors of first-line treatment failure: an exploratory study
    Kalemeera, F.
    Ndevahoma, St
    Mubita, M.
    Godman, Brian
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2022, 20 (06) : 915 - 921
  • [39] Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study
    Wang Feng
    Wang Junsheng
    Wu Tao
    Hong Yonggui
    Meng Xiangrui
    Ren Zhonghai
    Guo Yanzhen
    Yang Xiuli
    Shi Pei
    Yang Jiamei
    Fan Qingxia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [40] Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study
    Lam, Edward P.
    Moore, Cecilia L.
    Gotuzzo, Eduardo
    Nwizu, Chidi
    Kamarulzaman, Adeeba
    Chetchotisakd, Ploenchan
    van Wyk, Jean
    Teppler, Hedy
    Kumarasamy, Nagalingeswaran
    Molina, Jean-Michel
    Emery, Sean
    Cooper, David A.
    Boyd, Mark A.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2016, 32 (09) : 841 - 850
12345